Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 August Clinical trials Three-agent regimen provides ‘unprecedented’ PFS benefit in patients with relapsed multipl... Read more
2022 July Science Early experiments suggest modified IL-7 may be able to boost CAR-T cell therapy Read more
2022 July Clinical trials Circulating tumour cells and disease staging in newly diagnosed multiple myeloma patients Read more
2022 July Pharma News Fitusiran reduces bleeding events in patients with severe haemophilia Read more
2022 July Clinical trials PTCy plus TK is safe and effective in reducing GVHD in older patients with blood cancers Read more
Top
